Study finds potentially dangerous side-effect among PPI patients

Share this article:
Proton pump inhibitors (PPIs), the second best-selling therapeutic class of prescription drugs in 2004, may also be the cause of a potentially dangerous diarrhea in patients, a study appearing this week in the Journal of the American Medical Association (JAMA) found.
According to the study, patients using the prescription brands Prilosec (omeprazole), Prevacid (lansoprazole) and Nexium (esomeprazole), appear more prone to getting a potentially dangerous bacterial diarrhea caused by Clostridium difficile, or C-diff as it is known.
Patients taking the drugs were three times more likely to be diagnosed with the condition than those not taking the drugs. Those taking less potent H2 receptor agonists, which include Pepcid and Zantac, were two times more likely than non-users to get C-diff infections.
The study was conducted by Dr. Sandra Dial and colleagues at McGill University in Montreal.
Dial examined data on more than 18,000 patients in the U.K. from 1994 to 2004.
During that period of time, 1,672 cases of C-diff were diagnosed, and the numbers increased from less than 1 per 100,000 in 1994 to 22 per 100,000 in 2004.
According to an Associated Press report, a co-author in the study is a consultant for AstraZeneca, which markets Prilosec and Nexium, and Altana Pharma, which makes and markets Protonix (pantoprazole), in Europe. A spokesman for Wyeth, which markets Protonix in the U.S., said the company hadn't seen the research and declined comment, the AP report said.
The PPI therapeutic class was the second largest drug class by U.S. sales in 2004 with sales of approximately $13 billion, according to data from IMS Health.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...